We are live on ! Find out more
CTMX icon

CytomX Therapeutics
CTMX

114 hedge funds and large institutions have $275M invested in CytomX Therapeutics in 2021 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 36 increasing their positions, 45 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

4.35% less ownership

Funds ownership: 87.2% → 82.85% (-4.4%)

7% less funds holding

Funds holding: 122 → 114 (-8)

20% less repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 45

23% less capital invested

Capital invested by funds: $359M → $275M (-$83.8M)

41% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 17

96% less call options, than puts

Call options by funds: $9K | Put options by funds: $222K

Holders
114
Holders Change
-8
Holders Change %
-6.56%
% of All Funds
2%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
36
Reduced
45
Closed
17
Calls
$9K
Puts
$222K
Net Calls
-$213K
Net Calls Change
+$6K

Top Buyers

Rank Fund Capital Flow
1
CS
Candriam SCA
Luxembourg
+$5.23M
2
GPP
Great Point Partners
Connecticut
+$2.68M
3
Victory Capital Management
Victory Capital Management
Texas
+$2.14M
4
ACM
Altium Capital Management
New York
+$1.99M
5
Millennium Management
Millennium Management
New York
+$1.82M

Top Sellers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
-$10.4M
2
Citadel Advisors
Citadel Advisors
Florida
-$4.12M
3
Squarepoint
Squarepoint
New York
-$3.79M
4
State Street
State Street
Massachusetts
-$3.1M
5
Morgan Stanley
Morgan Stanley
New York
-$2.77M
Name Holding Trade Value Shares
Change 		Change in
Stake
SCM
26
Soleus Capital Management
Connecticut
$1.33M +$1.4M +261,050 New
GCP
27
GSA Capital Partners
United Kingdom
$1.27M +$1.33M +249,146 New
Axa
28
Axa
France
$1.18M +$1.24M +231,600 New
N
29
Nuveen
North Carolina
$1.17M +$173K +32,365 +17%
Bank of New York Mellon
30
Bank of New York Mellon
New York
$1.07M +$83.5K +15,591 +8%
Two Sigma Advisers
31
Two Sigma Advisers
New York
$1.02M -$899K -167,900 -45%
Russell Investments Group
32
Russell Investments Group
United Kingdom
$846K -$11K -2,053 -1%
Charles Schwab
33
Charles Schwab
California
$837K -$1.85M -345,671 -68%
Rafferty Asset Management
34
Rafferty Asset Management
New York
$806K -$198K -36,985 -19%
UBS Group
35
UBS Group
Switzerland
$800K +$706K +131,922 +522%
VRS
36
Virginia Retirement Systems
Virginia
$765K +$175K +32,600 +28%
HF
37
HRT Financial
New York
$759K +$799K +149,176 New
AAA
38
Affinity Asset Advisors
New York
$636K +$268K +50,000 +67%
PAG
39
Private Advisor Group
New Jersey
$634K +$215K +40,177 +48%
Susquehanna International Group
40
Susquehanna International Group
Pennsylvania
$620K +$66.5K +12,420 +11%
AGA
41
Altrinsic Global Advisors
Connecticut
$611K – – –
Morgan Stanley
42
Morgan Stanley
New York
$601K -$2.77M -517,805 -81%
Swiss National Bank
43
Swiss National Bank
Switzerland
$591K – – –
PAM
44
Panagora Asset Management
Massachusetts
$574K +$102K +19,123 +20%
Barclays
45
Barclays
United Kingdom
$564K -$85.3K -15,928 -13%
Citigroup
46
Citigroup
New York
$557K -$1.03M -191,688 -64%
SO
47
STRS Ohio
Ohio
$544K -$47.6K -8,900 -8%
PP
48
PDT Partners
New York
$539K +$161K +30,064 +40%
Two Sigma Investments
49
Two Sigma Investments
New York
$518K +$93.7K +17,509 +21%
PVI
50
Pura Vida Investments
New York
$506K -$7.87K -1,470 -1%
1
2
3 4 5

CTMX Hedge Fund Activity: Q3 2021 in Review

114 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q3 2021, worth a combined $275M — down 23% from $359M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of CTMX and 10 opened new positions — a net loss of 7 holders — while 45 trimmed existing stakes and 36 added.

The largest buyer was Candriam SCA, adding an estimated $5.23M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $10.4M sold.

  • 114 institutional investors held CytomX Therapeutics (CTMX) as of Q3 2021, down from 122 in Q2 2021.
  • Funds reported $275M of CytomX Therapeutics stock for Q3 2021, down 23% quarter-over-quarter.
  • 10 funds opened new CytomX Therapeutics positions in Q3 2021 and 17 closed out, a net change of -7 holders.
  • The largest CytomX Therapeutics buyer in Q3 2021 was Candriam SCA, an estimated $5.23M added.
  • The largest CytomX Therapeutics seller in Q3 2021 was Perceptive Advisors, an estimated $10.4M sold.

Based on aggregated 13F filings for Q3 2021.